BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc.
(Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic
pharmaceutical company, today announced it has appointed
Carter Pate to its Board of
Directors, effective immediately. Mr. Pate will serve on the Audit
and Nominating and Corporate Governance Committees.
Mr. Pate leads a family-owned investment firm and serves on the
Board of Directors at multiple companies, including Global Step and
Advanced Emissions Solutions, Inc. He excels at leading companies
through moments of change to drive business objectives and redefine
their possibilities for growth.
John Celentano, Chairman of
Teligent's Board of Directors, commented on the appointment,
stating, "We are excited to have Carter join Teligent's Board.
Carter's years of experience have given him an abundance of
knowledge of various industries, and he has proven that he can help
shepherd businesses through significant business transitions to
reach their full potential. We know Carter will be a great
addition, and we look forward to collaborating with him as Teligent
continues on its strategic and financial efforts to strengthen its
balance sheet and reinvigorate its business."
Mr. Pate is the founder and Chief Executive Officer of
Carter Pate, LLC, a Family Private
Equity Investment Company, and has served as a Board Member to
public and private Boards of Directors since 2014. He is the former
Chief Executive Officer of Providence Service Corp DBA
LogistiCare, the largest non-emergency medical logistics
company for Medicare and Medicaid. Mr. Pate currently serves on the
Board of Optioncare Health and was the Chairman of the Board
of its predecessor, BioScrip Inc. Mr. Pate was elected Chairman of
the Board of the Red Lion Hotel Group in December 2019, and also serves as a member of the
Board for Advanced Emissions Solutions.
Prior to these roles, Mr. Pate had a career with
PricewaterhouseCoopers spanning nearly two decades, including his
service as a Global/United States Managing Partner of U.S. Advisory
and later the Health Care practice leader. In these roles he worked
with Fortune 500 companies and G-20 governments with a focus on
change management and cost realignment. For his first seven years
at PwC, Mr. Pate led PwC's restructuring practice. He is the author
of best-selling financial restructuring book, "The Phoenix Effect:
Nine Revitalizing Strategies No Business Can Do Without."
Mr. Pate said, "I am excited to be to joining Teligent's Board
of Directors, it is truly an honor. Currently, Teligent is going
through a financial transformation, and I am confident I will be
able to provide a diverse mindset with years of prior industry
experience to guide them into the future. Teligent is at a position
to be an industry leader, and I am ready to work with management
and their established Board of industry veterans to position them
for success."
Mr. Pate holds certifications as a Certified Public Accountant
and Certified Forensic Public Accountant. He obtained his
undergraduate degree in Accounting and a master's degree in
Accounting and Information Systems from University of Texas at Dallas.
Nasdaq Bid Price Rule Compliance Update
Teligent received notice from Nasdaq that the Company has
regained compliance with the minimum $1.00 bid price requirement for continued listing
set forth in Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule")
and this matter is now closed. Teligent has now regained compliance
with all requirements previously noted by Nasdaq. For additional
information, please see the Company's January 22, 2021 press release, available here:
http://investors.teligent.com/news-releases/news-release-details/teligent-regains-compliance-nasdaq-filing-requirements-and.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our
mission is to be a leading player in the specialty generic
prescription drug market. Learn more on our website
www.teligent.com.
Forward-Looking Statements and Information
This press release includes "forward-looking statements" that
are intended to qualify for the safe harbors from liability
provided by Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements other than statements of historical facts are
statements that could be deemed forward-looking. These statements
are based on current expectations, estimates, forecasts and
projections about the Company's business and the industry in which
the Company operates and the beliefs and assumptions of the
Company's management. Forward-looking statements can be identified
by the use of words such as "will," "may," "could," "should,"
"would," "believe," "depends," "expect," "goal," "anticipate,"
"forecast," "project," "future," "intend," "plan," "estimate,"
"target," "indicate," "outlook," and similar expressions of future
intent or the negative of such terms. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, these forward-looking statements are based on management's
current beliefs, expectations and assumptions and are subject to
risks and uncertainties. These statements are based on the
Company's current beliefs or expectations and are inherently
subject to various risks and uncertainties, including those set
forth under the caption "Risk Factors" in the prospectus supplement
relating to the Company's current At the Market offering and the
Company's most recent Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other periodic reports the Company files with the
Securities and Exchange Commission. Additionally, many of these
risks and uncertainties are currently amplified by and will
continue to be amplified by, or in the future may be amplified by,
the COVID-19 outbreak and the effects thereof on the Company's
future performance and results of operations. It is not possible to
predict or identify all such risks. There may be additional risks
that the Company considers immaterial or which are unknown. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements included in
this press release speak only as of the date hereof and, subject to
any continuing obligations under applicable law or any relevant
stock exchange rules, we expressly disclaim any obligation to
disseminate, after the date of this document, any updates or
revisions to any such forward-looking statements to reflect any
change in expectations or events, conditions or circumstances on
which any such statements are based.
Media:
Rachel Chesley /
Sarah Rosselet
TeligentCommunications@fticonsulting.com
Investors:
InvestorRelations@Teligent.com
View original
content:http://www.prnewswire.com/news-releases/teligent-inc-announces-appointment-of-carter-pate-to-board-of-directors-301232945.html
SOURCE Teligent, Inc.